Doug Cowart, Robert Bender, Sebastian Brunemeier, Vincent Kalish Ph.D, Robert Venuti, Doris Cully Ph.D, Craig Hartman Ph.D
Number of employees
Total funding ($M)
NIH, ADDF, Bioventures Investors
Loss of proteostasis, Altered intercellular communication, Cell Loss
Alzheimer's, Parkinson's, anxiety, depression
small molecule drugs
A new class of therapies to treat brain diseases.
A clinical-stage pharmaceutical company developing a new class of cognitive-enhancing small molecules: nomethiazoles, which act as nitric oxide donor prodrugs and GABA(A) positive allosteric modulators. This results in CREB activation, vasodilation, reduced neuroinflammation, and reduced excitotoxicity. This MoA is neuroprotective in many animal models of CNS disease and cognitive decline. Revivo has been funded by the NIH, ADDF, and private venture capital, and we are raising capital for our clinical trials now.